8-K
OneMedNet Corp (ONMD)
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 31, 2025
ONEMEDNET
CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 001-40386 | 86-2076743 |
|---|---|---|
| (State<br>or other jurisdiction<br><br> <br>of<br>incorporation) | (Commission<br><br> <br>File<br>Number) | (I.R.S.<br>Employer<br><br> <br>Identification<br>No.) |
| 6385Old Shady Oak Road, Suite 250<br><br> <br>EdenPrairie, MN 55344<br><br> <br>(Address<br> of Principal Executive Offices) (Zip Code) | ||
| --- |
Registrant’s
telephone number, including area code: 800-918-7189
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written<br> communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencements<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common<br> Stock, $0.0001 par value per share | ONMD | The<br> Nasdaq Stock Market LLC |
| Redeemable<br> Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share | ONMDW | The<br> Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item<br>5.02. | Departure<br> of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;<br> Compensatory Arrangements of Certain Officers. |
|---|
As previously disclosed in a Current Report on Form 8-K filed on August 30, 2024 (the “Prior Report”), the board of directors (the “Board”) of OneMedNet Corporation (the “Company”) appointed Robert Golden to serve as Chief Financial Officer (“CFO”) on an interim basis.
On January 31, 2025, the Board appointed Mr. Golden as CFO of the Company on a permanent basis. In connection with his permanent appointment as CFO, in addition other amounts previously reported, Mr. Golden will also receive a cash bonus of $25,000 and a grant of restricted stock units equal to $25,000, which will be fully vested on the grant date. The disclosure in the Prior Report regarding Mr. Golden is incorporated by reference in this filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 6, 2025
| ONEMEDNET<br> CORPORATION | |
|---|---|
| By: | /s/Aaron Green |
| Aaron<br> Green | |
| Chief<br> Executive Officer |